A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies

Trial Profile

A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Emibetuzumab (Primary) ; Erlotinib; Gefitinib
  • Indications Lymphoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2014 Planned End Date changed from 1 Oct 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 02 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top